Absence of sibutramine effect on spontaneous anxiety in rats.
INTRODUSTION: Sibutramine has been described as a drug recommended for treatment of obesity, since it has the ability to inhibit the reuptake of serotonin and noradrenaline in the central nervous system, thereby increasing energy expenditure.


OBJECTIVE
Investigate the anxiogenic and anxiolytic effects of acute and chronic treatment with sibutramine in rats submitted to the task of the elevated plus-maze.


METHODS
Diazepam was used as a positive control for the anxiolytic effect, and the task of the elevated plus-maze showed sensitivity to detect the effect. In the chronic treatment, sibutramine was ingested for a period of two months.


RESULTS
The acute and chronic treatments at the studied dose, which is described to produce a maximum effect of anti-obesity in rats, did not interfere with anxiety.


CONCLUSIONS
The acute and chronic administration of sibutramine is not related to anxiolytic or anxiogenic effects.
Frassetto
Silvana S
SS
Universidade Luterana do Brazil, Canoas, RS, Brazil. vana@terra.com.br
Alves
Isis O
IO
Santos
Marislane M
MM
Schmidt
Ana E S
AE
Lopes
Janaína J
JJ
Oliveira
Paulo A
PA
Vinagre
Anapaula S
AS
Pereira
Patrícia
P
D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000494:pharmacology*; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology*; D001007:Anxiety / Q000188:drug therapy*; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000494:pharmacology*; D004195:Disease Models, Animal; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D014151:Anti-Anxiety Agents; D019440:Anti-Obesity Agents; D003503:Cyclobutanes; C058254:sibutramine